Sylwia Nowak Hauman
About Sylwia Nowak Hauman
Sylwia Nowak Hauman (age 50) was appointed Chief Financial Officer and Principal Financial and Accounting Officer of FOXO Technologies Inc. on September 23, 2025, bringing 25+ years of finance leadership across pharma/biotech and FDA-regulated companies; she is a Certified Accountant with a Master’s in Finance and Banking from Lodz University and is qualified in US GAAP and IFRS . She certified FOXO’s Q3 2025 Form 10-Q under SOX 302 and 906, affirming disclosure controls and fair presentation of financials, signaling accountability for internal control over financial reporting . Company performance context during her onboarding: healthcare net revenues rose to $3.5M in Q3 2025 vs $1.2M in Q3 2024, and to $11.9M for 9M 2025 vs $1.2M for 9M 2024, amid significant financing and capital structure changes .
Past Roles
| Organization | Role | Years | Strategic impact |
|---|---|---|---|
| Aditxt | VP, Corporate Controller | May 2022 – Sep 2024 | Finance leadership in biotech; US GAAP/IFRS controls |
| Accord Healthcare | Finance Director – Sales & Gross to Net | Jan 2020 – Apr 2022 | Pricing and gross-to-net analytics in pharma ops |
| Air Liquide Advanced Materials | Controller | Sep 2018 – Aug 2020 | Operational finance in advanced materials |
| Payall Payment Systems, Inc. | VP of Finance | Sep 2024 – Present | Fintech finance leadership concurrent with FOXO CFO |
| Lonza; Johnson & Johnson; Alvogen; Pearsanta | Various finance roles | Not disclosed | Multinational pharma/biotech finance experience |
| Unilever; Avon | Roles in FDA-regulated companies | Not disclosed | Compliance and controls in regulated environments |
External Roles
| Organization | Role | Years | Notes |
|---|---|---|---|
| Payall Payment Systems, Inc. | VP of Finance | Sep 2024 – Present | Continues alongside FOXO CFO appointment in Sep 2025 |
| Address (for filings) | Executive officer address | 2025 | 477 South Rosemary Ave, Suite 224, West Palm Beach, FL 33401 |
Fixed Compensation
| Component | Value | Effective date | Source |
|---|---|---|---|
| Base salary | $200,000 | Sep 23, 2025 | Appointment 8-K Item 5.02 |
| Target/possible bonus | $25,000 | Sep 23, 2025 | Appointment 8-K Item 5.02 |
Performance Compensation
| Incentive type | Metric | Weighting | Target | Actual | Payout | Vesting |
|---|---|---|---|---|---|---|
| Annual cash bonus (possible) | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Up to $25,000 | Not disclosed |
No RSU/PSU/option grant specifics for Ms. Hauman are disclosed in available filings through Nov 10, 2025; company-wide, no stock options were granted in 2025 YTD, and restricted stock saw forfeitures, suggesting limited new equity issuance in the period .
Equity Ownership & Alignment
| Item | Detail |
|---|---|
| Beneficial ownership (common/preferred) | Ms. Hauman is not listed among beneficial owners or named executive officers in DEF 14C (Record Date Sep 10, 2025) or in the Jan 6, 2025 DEF 14A tables . |
| Options/RSUs (vested/unvested) | No individual grants disclosed for Ms. Hauman in Q3 2025 filings; company disclosed no option grants in 2025 and RSU forfeitures . |
| Ownership guidelines/pledging/hedging | No disclosures found specific to Ms. Hauman in available filings . |
Employment Terms
| Term | Disclosure |
|---|---|
| Start date | Sep 23, 2025 (appointed CFO; Principal Financial & Accounting Officer) |
| Contract term/expiration | Not disclosed |
| Severance provisions | Not disclosed |
| Change-of-control treatment | Not disclosed for CFO role; broader capital structure changes detailed separately in DEF 14C/DEF 14A |
| Clawback provisions | Not disclosed |
| Non-compete / non-solicit | Not disclosed |
| Family relationships | None with directors/executives |
| Education/credentials | Certified Accountant; Master’s in Finance & Banking (Lodz University); US GAAP/IFRS qualified |
Performance & Track Record (Company context around tenure)
| Metric | Period 1 | Period 2 |
|---|---|---|
| Healthcare net revenues ($USD) | Q3 2024: $1.2M | Q3 2025: $3.5M |
| Healthcare net revenues ($USD) | 9M 2024: $1.2M | 9M 2025: $11.9M |
- Ms. Hauman executed SOX 302 and 906 certifications for Q3 2025, covering disclosure controls, ICFR evaluation, and fraud/deficiency disclosures; she signed alongside the CEO on Nov 10, 2025 .
Compensation Structure Analysis
- Cash-heavy with disclosed base salary and a relatively small potential bonus ($25k), and no disclosed equity grants in the period—reduces immediate insider selling pressure but offers limited equity alignment unless future grants occur .
- Company-wide equity issuance activity in 2025 emphasized preferred stock and capital structure changes rather than employee option grants; restricted stock saw forfeitures, indicating tightening equity programs during restructuring .
Related Party / Governance Context (Company-level backdrop)
- Majority voting control concentrated via Series A Preferred and voting agreements with RHI and affiliated holders, materially affecting governance; this is a company-level factor during Ms. Hauman’s tenure but not specific to her compensation .
- Preferred stock terms (Series A) and special meeting proposals materially alter dilution and voting dynamics; relevant for assessing overall incentive alignment in the near term .
Investment Implications
- Alignment: Absent disclosed equity awards for Ms. Hauman to date and a modest bonus potential, near-term pay-for-performance linkage appears limited; monitor future grants or performance-based awards to improve alignment .
- Retention risk: $200k salary with small bonus and no disclosed severance/change-of-control protections may indicate standard employment terms; watch subsequent filings for employment agreement details that could affect retention incentives .
- Trading signals: Lack of disclosed equity grants and no Form 4 activity evident in filings reduces insider selling pressure; however, company-level dilution and voting dynamics from preferred conversions create overhang and governance concentration, which can influence equity issuance to executives later .
- Execution capability: Extensive pharma/biotech and regulated industry finance background plus SOX certifications support control rigor; improved revenue run-rate in healthcare segment provides operational context during her onboarding period .